1 insider bought shares over the last 90 days, the latest filed 24 Aug 2026.
Mesoblast Limited is a listed company based in Australia. Its insiders report their share dealings to ASX. From 18 October 2025 to 18 October 2026, the disclosure feed for Mesoblast Limited logged 17 filings by 4 insiders.
Both sides are active: 1 purchase and 1 sale, from 1 insider and 1 insider respectively. No amount is published for 2 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive.
Across the 2,222 companies tracked on its exchange, the median is 3 filings; at 17 filings, this issuer sits above that mark. Our records for Mesoblast Limited go back to 2026, with 1 purchase and 1 sale on the open market in total.
The clock since the last published purchase (24 August 2026) now reads 54 days. Filings reach the ASX feed a median of 2 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
Every figure here comes from the filings published by ASX and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Mesoblast Limited Strong Buy (bullish), based on 3 analysts. Average price target: A$3.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
17 of 17 declarations
Mesoblast Limited is a biopharmaceutical company focused on developing cellular therapies. It is listed on the Australian Securities Exchange (XASX).
Headquarters: Australia · Wikipedia article
Source: Wikidata (CC0).